Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2016; 22(11): 3069-3077
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3069
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3069
Metastatic gastric cancer treatment: Second line and beyond
Marwan Ghosn, Hampig Raphael Kourie, Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Samer Tabchi, Mustapha Tehfe, Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montréal QC H3T 1J4, Canada
Author contributions: Tabchi S, Tehfe M and Kourie HR initiated the review; Kourie HR, and Tabchi S performed the review and wrote and analyzed the data; Ghosn M, Tabchi S, Kourie HR and Tehfe M reviewed the paper.
Conflict-of-interest statement: The conflict interest of the corresponding author are attached to this file.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Mustapha Tehfe, Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, 2900 Boulevard Edouard-Montpetit, Montréal QC H3T 1J4, Canada. matohfe@gmail.com
Telephone: +1-514-4974602
Received: October 16, 2015
Peer-review started: October 17, 2015
First decision: November 13, 2015
Revised: November 27, 2015
Accepted: December 30, 2015
Article in press: December 30, 2015
Published online: March 21, 2016
Peer-review started: October 17, 2015
First decision: November 13, 2015
Revised: November 27, 2015
Accepted: December 30, 2015
Article in press: December 30, 2015
Published online: March 21, 2016
Core Tip
Core tip: Patients with advanced gastric cancer who progress after first line therapy are usually perceived as unfit for additional treatments and are therefore denied life prolonging treatments which can also improve quality of life. We herein review the available evidence in favor of undertaking therapeutic interventions in these patients, be it conventional cytotoxic therapies or targeted therapies.